CPC C07K 14/4756 (2013.01) [C12N 15/907 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)] | 35 Claims |
1. A method of treating a cardiovascular disease or condition in a subject, comprising administering between 0.1 mcg/kg and 5 mg/kg of a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb).
|